Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III survodutide in adults with non-cirrhotic NASH/MASH and F2–F3 fibrosis
jRCT2031240540Phase 3Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2024
- Modality
- Peptides
01
Overview
Phase 3, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) and hepatic fibrosis comparing survodutide weekly injection with placebo weekly injection (2 arms). Primary endpoints: Resolution of MASH without worsening of liver fibrosis (Part 1), Improvement in liver fibrosis by at least 1 stage without worsening of MASH (Part 1) and 1 more. Started Dec 2024; status: recruiting.
02
Drugs
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)hepatic fibrosis
Beyond the preview
Go deeper on jRCT2031240540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240540.